Invivyd (IVVD) Price-to-Projected Revenue Ratio

Invivyd, Inc. (IVVD) relies on external contractors for antibody testing and is implementing robotics for 24/7 drug screening. The forward price-to-sales valuation trend demonstrates volatility, with the 2.90 mark indicating the current valuation level. High business scalability allows the company to rapidly capture the global market with minimal production costs following drug approval.

IVVD (Invivyd) Price-to-Projected Revenue Ratio history from 08/16/2024 to 11/13/2026

invivyd.com (IVVD) - metric breakdowns and financial figures

- current price and projected stock value:

Stock Price Invivyd|IVVD - Analyst Median Target

- market capitalization details:

Market Value IVVD|IVVD - Business Value

- book value of equity indicators:

Accounting Value per Share Invivyd, Inc.|IVVD - Company Book Value|Market Capitalization to Book Value Ratio invivyd.com|IVVD - Company Total Asset Base

- company total debt and liquidity indicators:

- net income and valuation multiples indicators:

IVVD - Net Financial Result|Expected Profit Invivyd, Inc.|IVVD - Price to Earnings Multiple|Forward P/E Multiple Invivyd|IVVD - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio IVVD|IVVD - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Invivyd, Inc.|IVVD - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months invivyd.com|IVVD - Earnings per share growth in current year|Expected earnings per share growth for next year Invivyd, Inc.

- sales revenue and business income indicators:

IVVD - Company Revenue|Projected Sales Volume Invivyd|IVVD - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio IVVD

Initial company analysis:Invivyd Corp IVVD

The investment attractiveness of Invivyd, Inc. (IVVD) relies on the stability of its scientific core and expertise in securing FDA antibody approvals. This metric evaluates the ratio of current market capitalization to expected sales, determining the asset's margin of safety through projected P/S dynamics. A decline in this ratio, while maintaining the human capital potential of the Discovery platform, may indicate that the business is undervalued relative to its fundamental prospects.

Competitor analysis for Invivyd, Inc.

Forward P/S Multiple GILD (Gilead Sciences)|Market Cap to Expected Sales Ratio Cidara Therapeutics Corp (CDTX)|NVAX - Price-to-Projected Revenue Ratio|CVAC (CureVac Pharma) - Market Cap to Projected Revenue|VALN (Valneva SE) - Forward Price-to-Revenue Multiple|VIR (vir.bio) - Price-to-Projected Revenue Ratio|SIGA (SIGA Technologies) - Forward P/S Multiple|Emergent BioSolutions Inc (EBS) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AVIR (Atea Pharmaceuticals Inc)|Price-to-Projected Revenue Ratio ENTA (Enanta Pharmaceuticals, Inc)|Inovio Pharmaceuticals - Forward Price-to-Revenue Multiple|hillevax.com (HLVX) - Market Cap to Future Revenue Ratio|Kalaris Therapeutics - Forward P/S Multiple|DYAI (Dyadic International) - Market Cap to Projected Revenue|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|Talphera Corporation - Forward Price to Sales|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|Traws Therapeutics (TRAW) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Dogwood Therapeutics, Inc. (DWTX)|Qualigen Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple ALVR (AlloVir)|VBIV - Forward Price-to-Revenue Multiple|VIRI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Vaxart, Inc. VXRT